0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD19 > Human CD19 (20-291) Protein, His Tag

Human CD19 (20-291) Protein, His Tag

  • Synonym
    CD19,B4,CVID3,MGC12802
  • Source
    Human CD19 (20-291), His Tag (CD9-H52H2) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
    Predicted N-terminus: Pro 20
  • Molecular Characterization
    Online(Pro 20 - Lys 291) P15391-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 32.0 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by reduced SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) SDS-PAGE gel

Human CD19 (20-291), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
Human CD19 (20-291), His TagHuman CD19 (20-291), His Tag (Cat. No. CD9-H52H2) ELISA bioactivity

Immobilized FMC63 MAb at 2 μg/mL (100 μL/well) can bind Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) with a linear range of 10-78 ng/mL (QC tested).

Human CD19 (20-291), His TagHuman CD19 (20-291), His Tag (Cat. No. CD9-H52H2) ELISA bioactivity

Immobilized Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind FMC63 (Mouse IgG2a) with a linear range of 2-13 ng/mL (Routinely tested).

Human CD19 (20-291), His TagHuman CD19 (20-291), His Tag (Cat. No. CD9-H52H2) ELISA bioactivity

Immobilized Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) at 0.1 μg/mL (100 μL/well) on MonRabTM Anti-His Tag (C-term) Antibody precoated (0.1 μg/well) plate, can bind FMC63 (Mouse IgG2a) with a linear range of 0.6-10 ng/mL (Routinely tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

FMC63 MAb (mouse lgG2a) captured on CM5 chip via anti-mouse antibodies surface, can bind Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) with an affinity constant of 2.95 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Human_FcRn_Heterodimer_Protein_SPR

Captured Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) on CM5 Chip via anti-His antibody, can bind FMC63 (mouse lgG2a) with an affinity constant of 2.01 nM as determined in SPR assay (Biacore T200 ) (Routinely tested).

Evaluation of CAR expression
FACS Analysis of anti-CD19 CAR Expression
Evaluation of CAR expression

293 cells were transfected with FMC63-scFv and RFP tag. 2x105 of the cells were first incubated with A. His Tag-protein control. B. Recombinant human CD19 (20-291), His Tag (Cat. No. CD9-H52H2, 10 μg/ml). C. Recombinant human CD19, His Tag (Cat. No. CD9-H52H2, 10 μg/ml) and FMC63 (Mouse anti-CD19 antibody). The FITC Anti-6xHis tag antibody was used to analyse with FACS. RFP was used to evaluate CAR (FMC63-scFv) expression and FITC was used to evaluate the binding activity of recombinant human CD19 (20-291), His Tag (Cat. No. CD9-H52H2).

Comments (0)

Order Details

Price(USD) : $352.00

Price(USD) : $2321.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:129 Details
  • Latest Research Phase:Approved
  • MORE

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop